Wissenschaftliche Arbeiten

Prof. Dr. Meral Beksaç

912 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT

    Bone Marrow Transplantation, 2022

    DOI 10.1038/s41409-021-01560-y PMID 35013536 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  2. EXTRAMEDULLARY DISEASE

    HemaSphere, 2022

    DOI 10.1097/01.hs9.0000829504.35798.64 2 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: ORCID

  3. Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)

    Blood, 2022

    DOI 10.1182/blood-2022-160004 2 Zitationen (OpenAlex) Quelle: ORCID

  4. Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA

    Leukemia Research, 2022

    DOI 10.1016/j.leukres.2022.106948 PMID 36108425 10 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  5. Extramedullary disease in multiple myeloma: a systematic literature review

    Blood Cancer Journal, 2022

    DOI 10.1038/s41408-022-00643-3 PMID 35314675 239 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  6. First Experience of 11C-Methionine PET in Multiple Myeloma in Turkey

    The Turkish Journal of Hematology, 2022

    DOI 10.4274/tjh.galenos.2021.2020.0625 PMID 33355742 Frei zugänglicher VolltextQuelle: ORCID

  7. First Experience of11C-Methionine PET in Multiple Myeloma in Turkey,Multipl Myelomada11C-Metiyonin PET’in İlk Türkiye Deneyimi

    Turkish Journal of Hematology, 2022

    DOI 10.4274/tjh.galenos.2020.2020.0625 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: ORCID

  8. Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study

    American Journal of Hematology, 2022

    DOI 10.1002/ajh.26536 PMID 35293006 9 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  9. Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial

    American Journal of Hematology, 2022

    DOI 10.1002/ajh.26480 PMID 35089607 10 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  10. Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial

    EJHaem, 2022

    DOI 10.1002/jha2.548 PMID 36467842 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  11. Is Quantification of Measurable Clonal Plasma Cells in Stem Cell Grafts (gMRD) Clinically Meaningful?

    Frontiers in Oncology, 2022

    DOI 10.3389/fonc.2022.800711 PMID 35280810 5 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  12. Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies

    Blood, 2022

    DOI 10.1182/blood-2022-159710 6 Zitationen (OpenAlex) Quelle: ORCID

  13. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study

    The Lancet Oncology, 2022

    DOI 10.1016/s1470-2045(22)00019-5 PMID 35151415 101 Zitationen (Europe PMC) Quelle: ORCID

  14. Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis

    Clinical Lymphoma Myeloma and Leukemia, 2022

    Quelle: ORCID

  15. MM-086 Real-World Experience With Isatuximab (Isa) in Patients With Relapsed and/or Refractory Multiple Myeloma: IONA-MM First Interim Analysis

    Clinical Lymphoma, Myeloma and Leukemia, 2022

    DOI 10.1016/s2152-2650(22)01590-7 6 Zitationen (OpenAlex) Quelle: ORCID

  16. MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab plus Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

    Blood, 2022

    DOI 10.1182/blood-2022-159756 33 Zitationen (OpenAlex) Quelle: ORCID

  17. Manual Versus Automated Volume Reduction of Cord Blood

    European Journal of Therapeutics, 2022

    DOI 10.54614/eurjther.2021.0029 Frei zugänglicher VolltextQuelle: ORCID

  18. Novel targets detected by next generation sequencing among triple refractory patients can be clinically targetable

    Clinical Lymphoma Myeloma and Leukemia, 2022

    Quelle: ORCID

  19. OPTIMISMM Subanalyse: Sicherheit von Pomalidomid (POM), Bortezomib (BORT) und Dexamethason (DEX) (PVd) Behandlung ( Tx) nach einer vorherigen Therapielinie (LoT) bei Patienten (pts) mit rezidiviertem oder refraktarem multiplen Myelom (RRMM)

    Oncology Research and Treatment, 2022

    Quelle: ORCID

  20. Pomalidomide (POM), bortezomib (BORT), and dexamethasone (DEX) after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): a safety subanalysis of the phase 3 OPTIMISMM trial

    Oncology Research and Treatment, 2022

    Quelle: ORCID

  21. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics

    European Journal of Haematology, 2022

    DOI 10.1111/ejh.13706 PMID 34496096 10 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  22. Pomalidomide, bortezomib, and dexamethasone in lenalidomide-pretreated multiple myeloma: A subanalysis of OPTIMISMM by frailty

    Journal of Clinical Oncology, 2022

    DOI 10.1200/jco.2022.40.16_suppl.8024 3 Zitationen (OpenAlex) Quelle: ORCID

  23. Post-authorization safety of lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma in Turkey

    Clinical Lymphoma Myeloma and Leukemia, 2022

    Quelle: ORCID

  24. Pretransplant Consolidation Therapies Improve the Outcome of Myeloablative Allogeneic Transplantation in Adults with Ph-negative Acute Lymphoblastic Leukemia

    Clinical Lymphoma, Myeloma and Leukemia, 2022

    DOI 10.1016/j.clml.2022.02.007 PMID 35410758 2 Zitationen (Europe PMC) Quelle: ORCID

  25. Prophylactic defibrotide is effective for acute graft versus host disease as well as sinusoidal obstructive syndrome

    Bone Marrow Transplantation, 2022

    Quelle: ORCID

  26. Real-World Experience With Isatuximab (Isa) in Patients With Relapsed and/or Refractory Multiple Myeloma: IONA-MM First Interim Analysis

    Clinical Lymphoma Myeloma and Leukemia, 2022

    Quelle: ORCID

  27. Real-world experience with isatuximab in patients with relapsed and/or refractory multiple myeloma (RRMM): IONA-MM first interim analysis

    Clinical Lymphoma Myeloma and Leukemia, 2022

    Quelle: ORCID

  28. Single Center Real World Data That Compares Autologous Stem Cell Transplant in the Era of Anti-CD38 Monoclonal Antibody Based Treatments for AL Amyloidosis

    Blood, 2022

    DOI 10.1182/blood-2022-170132 Quelle: ORCID

  29. Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study

    Blood, 2022

    DOI 10.1182/blood-2022-163483 14 Zitationen (OpenAlex) Quelle: ORCID

  30. The Impact of CD34+Cell and Immunefector Cell Dose on Transplant Outcomes

    Blood, 2022

    DOI 10.1182/blood-2022-155998 Quelle: ORCID

  31. The efficacy and safety of second allogeneic hematopoietic stem cell transplantation

    Journal of Clinical Oncology, 2022

    Quelle: ORCID

  32. Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019

    British Journal of Haematology, 2022

    DOI 10.1111/bjh.18025 PMID 35166376 13 Zitationen (Europe PMC) Quelle: ORCID

  33. İkinci Allojenik Kök Hücre Nakli: Gerçek Yaşam Verisi

    LLM Dergi, 2022

    DOI 10.5578/llm.20229804 Frei zugänglicher VolltextQuelle: ORCID

  34. P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL

    HemaSphere, 2022

    DOI 10.1097/01.hs9.0000829588.31575.a9 7 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  35. P957: CARFILZOMIB, LENALIDOMIDE, DEXAMETHASONE FOLLOWED BY A SECOND AUTO-HCT IS AN EFFECTIVE STRATEGY IN FIRST RELAPSE MULTIPLE MYELOMA: A STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT

    HemaSphere, 2022

    DOI 10.1097/01.hs9.0000846696.43332.f6 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  36. P901: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN LENALIDOMIDE–PRETREATED MULTIPLE MYELOMA: A SUBANALYSIS OF OPTIMISMM BY FRAILTY

    HemaSphere, 2022

    DOI 10.1097/01.hs9.0000846476.91419.a1 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  37. Impfempfehlungen beim Multiplen Myelom: ein Konsensbericht des European Myeloma Network

    Kompass Onkologie, 2022

    DOI 10.1159/000522451 Quelle: OpenAlex

  38. Is It Safe to Continue Allogeneic Hematopoietic Cell Transplantation Via Cryopreservation during COVID-19 Pandemic?

    Transplantation and Cellular Therapy, 2022

    DOI 10.1016/s2666-6367(22)00500-0 Frei zugänglicher VolltextQuelle: OpenAlex

  39. P28: RESPONSE AND VACCINATION STATUS OR LACK OF IMMUNOPARESIS ARE ASSOCIATED WITH BETTER OUTCOME FOLLOWING COVID-19 INFECTION AMONG PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA: A SINGLE CENTER EXPERIENCE ON 110 PATIENTS

    HemaSphere, 2022

    DOI 10.1097/01.hs9.0000829684.63064.c2 Frei zugänglicher VolltextQuelle: OpenAlex

  40. P-258: Real-world experience with isatuximab in patients with relapsed and/or refractory multiple myeloma (RRMM): IONA-MM first interim analysis

    Clinical Lymphoma Myeloma & Leukemia, 2022

    DOI 10.1016/s2152-2650(22)00588-2 Quelle: OpenAlex

  41. P-099: Novel targets detected by next generation sequencing among triple refractory patients can be clinically targetable

    Clinical Lymphoma Myeloma & Leukemia, 2022

    DOI 10.1016/s2152-2650(22)00429-3 Quelle: OpenAlex

  42. P-277: Carfilzomib, lenalidomide and dexamethasone followed by a second autologous hematopoietic cell transplantation is an effective strategy in first-relapsed multiple myeloma

    Clinical Lymphoma Myeloma & Leukemia, 2022

    DOI 10.1016/s2152-2650(22)00607-3 Quelle: OpenAlex

  43. Poster: MM-086 Real-World Experience With Isatuximab (Isa) in Patients With Relapsed and/or Refractory Multiple Myeloma: IONA-MM First Interim Analysis

    Clinical Lymphoma Myeloma & Leukemia, 2022

    DOI 10.1016/s2152-2650(22)01094-1 Quelle: OpenAlex

  44. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies

    Turkish Journal of Hematology, 2021

    DOI 10.4274/tjh.galenos.2021.2021.0287 PMID 34521187 7 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  45. Significance of inhibitory maternal killer-cell immunoglobulin-like receptor (KIR) and fetal KIR ligand genotype combinations in placenta related obstetric complications

    Journal of Reproductive Immunology, 2021

    DOI 10.1016/j.jri.2021.103425 PMID 34607283 4 Zitationen (Europe PMC) Quelle: OpenAlex

  46. The Efficacy of Therapeutic Thrombocytapheresis in Patients with Thrombocytosis

    Journal of Ankara University Faculty of Medicine, 2021

    DOI 10.4274/atfm.galenos.2021.08860 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: ORCID

  47. The Influence of ATG on the Outcomes of Patients With AML at the Time of Unrelated Donor Transplantation

    Journal of Ankara University Faculty of Medicine, 2021

    DOI 10.4274/atfm.galenos.2021.95866 Frei zugänglicher VolltextQuelle: ORCID

  48. A Bottom-Up Proteomic Approach in Bone Marrow Plasma Cells of Newly Diagnosed Multiple Myeloma Patients

    Current Proteomics, 2021

    DOI 10.2174/1570164617999201124142232 Quelle: ORCID

  49. A Novel Early Relapse Prediction Score Based on Age, ISS and Disease Status at the Time of Transplant in Patients with Newly Diagnosed Multiple Myeloma. a Study of the EBMT Chronic Malignancies Working Party

    Blood, 2021

    DOI 10.1182/blood-2021-147001 4 Zitationen (OpenAlex) Quelle: ORCID

  50. A model integrating Killer Immunoglobulin-like Receptor (KIR) haplotypes for risk prediction of COVID-19 clinical disease severity

    Immunogenetics, 2021

    DOI 10.1007/s00251-021-01227-4 PMID 34536086 4 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID